CA1187796A - Pharmaceutical formulation - Google Patents
Pharmaceutical formulationInfo
- Publication number
- CA1187796A CA1187796A CA000386670A CA386670A CA1187796A CA 1187796 A CA1187796 A CA 1187796A CA 000386670 A CA000386670 A CA 000386670A CA 386670 A CA386670 A CA 386670A CA 1187796 A CA1187796 A CA 1187796A
- Authority
- CA
- Canada
- Prior art keywords
- amoxycillin
- desiccant
- clavulanic acid
- composition
- anyone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 29
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims abstract description 28
- 239000002274 desiccant Substances 0.000 claims abstract description 18
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960003022 amoxicillin Drugs 0.000 claims abstract description 17
- 229960003324 clavulanic acid Drugs 0.000 claims abstract description 17
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims abstract description 17
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims abstract description 11
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000000429 sodium aluminium silicate Substances 0.000 claims description 4
- 235000012217 sodium aluminium silicate Nutrition 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000004111 Potassium silicate Substances 0.000 claims 1
- 239000000404 calcium aluminium silicate Substances 0.000 claims 1
- 235000012215 calcium aluminium silicate Nutrition 0.000 claims 1
- WNCYAPRTYDMSFP-UHFFFAOYSA-N calcium aluminosilicate Chemical compound [Al+3].[Al+3].[Ca+2].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O WNCYAPRTYDMSFP-UHFFFAOYSA-N 0.000 claims 1
- 229940078583 calcium aluminosilicate Drugs 0.000 claims 1
- 235000019353 potassium silicate Nutrition 0.000 claims 1
- 229940074415 potassium silicate Drugs 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000002253 acid Substances 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
- 229920003084 Avicel® PH-102 Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 239000004859 Copal Substances 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000782205 Guibourtia conjugata Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8031298 | 1980-09-27 | ||
| GB8031298 | 1980-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1187796A true CA1187796A (en) | 1985-05-28 |
Family
ID=10516342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000386670A Expired CA1187796A (en) | 1980-09-27 | 1981-09-25 | Pharmaceutical formulation |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4537887A (instruction) |
| EP (1) | EP0049061B1 (instruction) |
| JP (1) | JPS5791921A (instruction) |
| AU (1) | AU549321B2 (instruction) |
| CA (1) | CA1187796A (instruction) |
| DE (1) | DE3172028D1 (instruction) |
| ES (1) | ES505803A0 (instruction) |
| GB (1) | GB2084016B (instruction) |
| GR (1) | GR75049B (instruction) |
| HK (1) | HK17386A (instruction) |
| IE (1) | IE51597B1 (instruction) |
| MY (1) | MY8600353A (instruction) |
| NZ (1) | NZ198241A (instruction) |
| PT (1) | PT73686A (instruction) |
| ZA (1) | ZA816272B (instruction) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0080862B1 (en) * | 1981-12-02 | 1985-09-25 | Beecham Group Plc | Pharmaceutical formulation comprising beta-lactam antibiotics |
| JPS59104319A (ja) * | 1982-12-06 | 1984-06-16 | Chugai Pharmaceut Co Ltd | 抗菌剤およびそのキツト |
| ES2061623T3 (es) * | 1987-03-02 | 1994-12-16 | Brocades Pharma Bv | Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico. |
| US5211958A (en) * | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
| EP0330284B1 (en) * | 1988-02-25 | 1994-07-27 | Yamanouchi Europe B.V. | Process for the preparation of a pharmaceutical granulate |
| US5643902A (en) * | 1990-04-26 | 1997-07-01 | Pfizer Inc. | Veterinary treatment |
| GB9408117D0 (en) * | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
| GB9413542D0 (en) * | 1994-07-05 | 1994-08-24 | Smithkline Beecham Plc | Pharmaceutical formulations |
| EP0768980B1 (en) * | 1994-08-05 | 2001-11-07 | West Pharmaceutical Services Cornwall Limited | Container for moisture sensitive material and corresponding desiccating and reducing methods |
| GB9416600D0 (en) * | 1994-08-17 | 1994-10-12 | Smithkline Beecham Plc | Pharmaceutical formulation |
| DZ1926A1 (fr) * | 1994-09-03 | 2002-02-17 | Smithkline Beckman P L C | Formulations pharmaceutiques. |
| ES2079327B1 (es) * | 1994-12-13 | 1996-08-01 | Lilly Sa | Formulaciones farmaceuticas de cefaclor. |
| DZ2028A1 (fr) * | 1995-05-03 | 2002-10-23 | Smithkline Beecham Plc | Médicaments destinés au traitement d'infections bactériennes en pédiatrie. |
| US20030109503A1 (en) * | 1995-06-06 | 2003-06-12 | Smithkline Beecham P.L.C. | Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics |
| DE69617036T2 (de) * | 1995-09-07 | 2002-07-11 | Smithkline Beecham Corp., King Of Prussia | Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung |
| ITMI952354A1 (it) * | 1995-11-16 | 1997-05-16 | Smithkline Beecham Spa | Composizione farmaceutica |
| US5801796A (en) * | 1996-05-10 | 1998-09-01 | International Business Machines Corporation | Stacked parallax-free liquid crystal display cell |
| GB9617780D0 (en) * | 1996-08-24 | 1996-10-02 | Smithkline Beecham Plc | Method of treatment |
| US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| BR9807383A (pt) * | 1997-02-14 | 2000-03-14 | Smithkline Beecham Lab | Formulação farmacêutica que compreende amoxicilina e clavulanato |
| US6296871B1 (en) * | 1998-04-12 | 2001-10-02 | Ranbaxy Laboratories Limited | Stable solid pharmaceutical compositions containing enalapril maleate |
| US6177421B1 (en) | 1999-05-04 | 2001-01-23 | Fuisz International Ltd. | Amoxicillin and clavulanate composition |
| IE990159A1 (en) * | 1999-02-26 | 2000-09-20 | Fuisz Internat Ltd | Storage Stable Amoxycillin and Clavulanate Suspension Composition. |
| US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
| US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
| US7250176B1 (en) | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
| EP1206261B1 (en) * | 1999-08-16 | 2006-03-08 | Revaax Pharmaceuticals LLC | Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| US6426342B2 (en) * | 1999-08-16 | 2002-07-30 | Revaax Pharmaceuticals, Llc | Use of β-lactamase inhibitors as neuroprotectants |
| US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
| AU2001292185A1 (en) | 2000-10-12 | 2002-04-22 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
| CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| KR100456833B1 (ko) * | 2002-08-01 | 2004-11-10 | 주식회사 대웅 | 아목시실린 및 클라불라네이트를 함유하는 유핵정 |
| EP1902708A1 (de) * | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung |
| WO2009055038A1 (en) | 2007-10-26 | 2009-04-30 | Rexahn Pharmaceuticals, Inc. | Pharmaceutical formulation of clavulanic acid |
| CA2758029A1 (en) * | 2009-04-29 | 2011-11-04 | Rexahn Pharmaceuticals, Inc. | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders |
| SMT201900716T1 (it) | 2013-03-15 | 2020-01-14 | Braintree Laboratories Inc | Compresse orali di composizione farmaceutica a doppio uso di sali di solfato e metodi per il loro utilizzo |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE888444C (de) * | 1951-11-10 | 1953-08-31 | Benckiser Gmbh Joh A | Verfahren zum Tablettieren von hygroskopischen Praeparaten |
| US3432593A (en) * | 1963-09-18 | 1969-03-11 | Key Pharm Inc | Delayed and sustained release type pharmaceutical preparation |
| GB1209634A (en) * | 1967-06-29 | 1970-10-21 | Rit Rech Ind Therapeut | Stabilized antibiotic compositions for animal feeding and process for preparing them |
| DE2512247A1 (de) * | 1975-03-20 | 1976-10-14 | Thomae Gmbh Dr K | Gegen feuchtigkeit stabilisierte presslinge mit feuchtigkeitsempfindlichen inhaltsstoffen |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| JO984B1 (en) * | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | A dry pharmaceutical compound with a suitable dosage unit for oral administration |
| IL58461A0 (en) * | 1978-10-27 | 1980-01-31 | Beecham Group Ltd | Intramammary compositions comprising a clavulanic acid salt |
| US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
-
1981
- 1981-09-02 NZ NZ198241A patent/NZ198241A/xx unknown
- 1981-09-08 DE DE8181304086T patent/DE3172028D1/de not_active Expired
- 1981-09-08 EP EP81304086A patent/EP0049061B1/en not_active Expired
- 1981-09-10 ZA ZA816272A patent/ZA816272B/xx unknown
- 1981-09-14 GB GB8127649A patent/GB2084016B/en not_active Expired
- 1981-09-16 PT PT73686A patent/PT73686A/pt unknown
- 1981-09-23 GR GR66117A patent/GR75049B/el unknown
- 1981-09-25 IE IE2232/81A patent/IE51597B1/en not_active IP Right Cessation
- 1981-09-25 CA CA000386670A patent/CA1187796A/en not_active Expired
- 1981-09-25 ES ES505803A patent/ES505803A0/es active Granted
- 1981-09-25 AU AU75684/81A patent/AU549321B2/en not_active Expired
- 1981-09-28 JP JP56153513A patent/JPS5791921A/ja active Granted
-
1983
- 1983-10-05 US US06/539,099 patent/US4537887A/en not_active Expired - Lifetime
-
1986
- 1986-03-13 HK HK173/86A patent/HK17386A/en not_active IP Right Cessation
- 1986-12-30 MY MY353/86A patent/MY8600353A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US4537887A (en) | 1985-08-27 |
| PT73686A (pt) | 1981-10-01 |
| JPH0155244B2 (instruction) | 1989-11-22 |
| HK17386A (en) | 1986-03-21 |
| AU7568481A (en) | 1982-04-08 |
| GB2084016B (en) | 1985-04-17 |
| GR75049B (instruction) | 1984-07-12 |
| GB2084016A (en) | 1982-04-07 |
| AU549321B2 (en) | 1986-01-23 |
| EP0049061A1 (en) | 1982-04-07 |
| NZ198241A (en) | 1983-12-16 |
| ES8307095A1 (es) | 1983-06-16 |
| ZA816272B (en) | 1982-09-29 |
| EP0049061B1 (en) | 1985-08-28 |
| ES505803A0 (es) | 1983-06-16 |
| DE3172028D1 (en) | 1985-10-03 |
| IE51597B1 (en) | 1987-01-21 |
| IE812232L (en) | 1982-03-27 |
| MY8600353A (en) | 1986-12-31 |
| JPS5791921A (en) | 1982-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1187796A (en) | Pharmaceutical formulation | |
| US4441609A (en) | Pharmaceutical compositions | |
| US6194001B1 (en) | Tablet dosage form of clavulanic acid and amoxycillin comprising a trehalose excipient | |
| KR100397578B1 (ko) | 수분활성을조절한젤라틴캡슐제 | |
| FI110354B (fi) | Menetelmä farmaseuttisten rakeiden valmistamiseksi | |
| AU711441B2 (en) | Pharmaceutical formulation | |
| US6214359B1 (en) | Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant Streptococcus pneumoniae | |
| HU196708B (en) | Process for producing pharmaceutical composition comprising omeprazol and suitable for treating deseases of the digestive system | |
| KR20010080566A (ko) | 세푸록심 악세틸을 포함하는 조성물 | |
| HK129894A (en) | Tablet and granulate containing mesna as active agent | |
| EP0764031A1 (en) | Injectable formulations containing a desiccant | |
| AU771516B2 (en) | Drinkable ibuprofen pharmaceutical suspension | |
| US20070036732A1 (en) | Stable topiramate formulations | |
| WO1997017960A1 (en) | Pharmaceutical composition comprising amoxycillin and clavulanate and a desiccant | |
| KR810001316B1 (ko) | 안정성이 증가된 아목시실린함유 약제조성물의 제조방법 | |
| MXPA06002530A (es) | Forma de dosificacion oral, en forma de multiples particulas, formulada mediante fusion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |